Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10730628 | PMC |
| http://dx.doi.org/10.1007/s40265-023-01978-2 | DOI Listing |
Publication Analysis
Top Keywords
correction elacestrant
4
elacestrant approval
4
correction
1
approval
1
Similar Publications
Correction : Molecular Modeling Studies of Similar Molecules to Selective Estrogen Receptor Degrader Elacestrant as Inhibitors of SARS-COV-2.
Cell Biochem Biophys
January 2025
Department of Physics, University of Alberta, Edmonton, AB, Canada.
Correction: Elacestrant: First Approval.
Drugs
December 2023
Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.
Correction to: Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women.
Eur J Drug Metab Pharmacokinet
October 2020
Department of Clinical Pharmacology, Radius Health, Inc., 950 Winter Street, Waltham, MA, USA.
Article Synopsis
- The authors have identified inaccuracies in Table 2 of their previous work.
- They have proposed corrections to address these errors.
- The corrections aim to enhance the accuracy and reliability of the data presented in the table.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!